Bluejay Diagnostics Completes Patient Enrollment In SYMON-II Multicenter Clinical Validation Study
Bluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the successful completion of patient enrollment in its
Bluejay finished signing up all the patients needed to test their new quick diagnostic tool. When companies complete big testing steps like this, it shows progress—watch to see if the results come back strong.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.